Thanks for posting George and Bear. 

"The article titled: “A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing” by Gordon et al, identified BRD2/4 as a binding partner of viral protein E. Apabetalone was shown to disrupt this interaction."

I do not see the justification for the statement "Apabetalone was shown to disrupt this interaction" in the article.  This would seem to be a result of some follow-up work done in one of labs testing the anti-viral properties of the candidate drugs. Did I miss something?

Jupe